Decitabine - Janssen-Cilag/Otsuka Pharmaceutical
Alternative Names: 127716; 2'-deoxy-5-azacytidine; 2353-33-5; 4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one; 5-aza-2'-deoxycytidine; DAC; Dacogen; Decitabine mesylate; Deoxycytidine; Dezocitidine; E-7373; NSC-127716Latest Information Update: 28 Nov 2023
At a glance
- Originator Indiana University; SuperGen
- Developer Eisai Co Ltd; European Organisation for Research and Treatment of Cancer; Groupe Francophone des Myelodysplasies; HOVON Foundation; Italian Group for Haematological Diseases; Janssen-Cilag; Johnson & Johnson Innovative Medicine; M. D. Anderson Cancer Center; Novartis; Otsuka Pharmaceutical; Sidney Kimmel Cancer Center; Xian-Janssen
- Class Antineoplastics; Aza compounds; Deoxyribonucleosides; Pyrimidine nucleosides; Ribonucleosides; Small molecules
- Mechanism of Action Antimetabolites; DNA methylation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Acute myeloid leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes
- Phase III Chronic myelomonocytic leukaemia
- Phase I/II Malignant melanoma; Ovarian cancer
- No development reported Myelofibrosis; Solid tumours
- Discontinued Colorectal cancer
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for phase-I development in Myelofibrosis(Combination therapy, Treatment-experienced) in Spain (IV)
- 01 Oct 2023 Janssen Pharmaceuticals is now called Johnson & Johnson Innovative Medicine (Janssen Pharmaceuticals website, October 2023)
- 09 Jan 2023 Efficacy data from a phase III trial in Acute myeloid leukaemia presented at the 64th American Society of Hematology Annual Meeting and Exposition(ASH-Hem-2023)